Showing results (1-10 of 204) with videos related to
Sort By:
Pageof 21
British Journal of Cancer|December 21, 2006
Wait times for breast cancer careN Saint-Jacques, T Younis, R Dewar, et al.Current Oncology (Toronto, Ont.)|November 13, 2012
Chemotherapy uptake and wait times in early-stage non-small-cell lung cancerS Gray, J Bu, N Saint-Jacques, et al.Breast Cancer Research and Treatment|August 10, 2006
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozoleC Skedgel, D Rayson, R Dewar, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2006
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancerT Younis, D Rayson, R Dewar, et al.Breast (Edinburgh, Scotland)|January 9, 2007
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozoleC Skedgel, D Rayson, R Dewar, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2013
Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?C Skedgel, D Rayson, T YounisCurrent Oncology (Toronto, Ont.)|December 21, 2011
The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancerT Younis, D Rayson, C SkedgelBreast Cancer Research and Treatment|August 31, 2016
Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic reviewT Younis, D Rayson, S Jovanovic, et al.Current Oncology (Toronto, Ont.)|August 25, 2015
Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levelsN W D Lamond, C Skedgel, D Rayson, et al.Current Oncology (Toronto, Ont.)|July 4, 2008
The cost burden of trastuzumab and bevacizumab therapy for solid tumours in CanadaA Drucker, C Skedgel, K Virik, et al.Pageof 21